Last updated: June 2026. Most of the compounds named below are prescription or compounded products, and several are not FDA-approved for the uses men over 40 are chasing. Every clinical and regulatory claim links to a primary source that can be opened and checked.
A friend starts sermorelin. He says his sleep is better. He mentions CJC-1295, ipamorelin, BPC-157, testosterone, NAD+, and a website that sells most of it in a few clicks. That is how this question usually arrives for a man over 40: as a list of names, not a decision. The list is the problem. Six different things get sold under one trendy word, and the honest evidence behind them ranges from decades of large trials to a handful of rat studies. So the useful question is not “which one is best.” It is “how much do we actually know about each one, and who is standing between me and the vial.” Answer those, in order, and the rest sorts itself.
What is actually being sold under one word?
Six things, mostly. Testosterone, which is not technically a peptide but travels with this whole category. Sermorelin and CJC-1295, both growth-hormone-releasing compounds. Ipamorelin, a related GH secretagogue. BPC-157, marketed for tendons and gut healing. And NAD+, sold as precursors like nicotinamide riboside. Same aisle, wildly different evidence bases. The rest of this piece takes them one at a time, strongest evidence first.
Which compound has the most evidence, and why does that argue for more caution, not less?
Testosterone. The TRAVERSE trial, published in the New England Journal of Medicine in 2023, randomized 5,246 middle-aged and older men with diagnosed low testosterone and elevated cardiovascular risk to testosterone gel or placebo. It met its safety goal: no increase in major adverse cardiac events versus placebo [1]. It also found something less comforting sitting right beside that result: more atrial fibrillation in the testosterone group [1].
Put those two findings together and a pattern appears. The compound with the strongest evidence is also the one that most clearly needs monitoring, and only makes sense for men with labs confirming actual deficiency. The support medications that travel with it, HCG and enclomiphene among them, exist because using testosterone correctly is an ongoing process, not a single purchase. Strongest evidence, strongest case for a clinician. That is the pattern this whole piece keeps returning to.
What do sermorelin and CJC-1295 actually deliver?
Real movement in the numbers, modest movement in real life. Sermorelin is a fragment of natural growth-hormone-releasing hormone. In a 1992 study in the Journal of Clinical Endocrinology and Metabolism, older men given the active GHRH fragment twice daily for two weeks saw their growth hormone and IGF-1 shift back toward younger levels [2]. CJC-1295, the longer-acting version, raised GH and IGF-1 for days after a single dose in a 2006 study in the same journal [3].
Here is the catch. A 1997 study in Metabolism found single nightly GHRH injections were less effective than multiple daily doses, with only modest strength changes [4]. The hormones respond. The dosing schedule decides whether a man notices anything. That gap, between “the mechanism works” and “the payoff is modest,” is the honest summary for both compounds.
Why did ipamorelin’s best trial come back flat?
Because it did. Ipamorelin gets grouped with the other GH secretagogues, but its most rigorous human test was not about anti-aging or recovery at all. A randomized, placebo-controlled 2014 trial studied it in a postoperative hospital setting and missed its primary endpoint, with no statistically significant benefit over placebo (p = 0.15) [5]. That trial does not settle the gym and longevity claims one way or the other, since it was testing something different. But it is rare, careful human data in a category that mostly lacks it, and it did not show a win. Reason enough to rank it below sermorelin and CJC-1295, not to dismiss it outright.
Is BPC-157 proven, or just popular?
Popular, not proven. A 2025 systematic review in HSS Journal, the Hospital for Special Surgery’s publication, examined the BPC-157 literature and found it is nearly all preclinical, done in animals or cells, with no clinical safety data in humans and no FDA-approved indication [6]. The tendon-healing story that made BPC-157 famous is a rat story. There is no established human dose and no regulator standing behind what is actually in a given vial.
Its legal status is also mid-shift. BPC-157 sat on the FDA’s Category 2 “do not compound” list, then was removed from it in April 2026 after the nominations behind that listing were withdrawn, with a Pharmacy Compounding Advisory Committee meeting scheduled for July 23 to 24, 2026 to weigh whether it belongs on the approved bulk-substances list instead [9]. Removed from a do-not-compound list is not the same sentence as approved and proven safe. It is limbo. For a compound with this little human data, that limbo is exactly why it belongs in the hands of someone who knows a patient’s history, if it belongs anywhere yet.
What does the NAD+ research actually show?
Less than the marketing implies, but nothing alarming either. NAD+ is a coenzyme tied to energy metabolism that declines with age, which is why it became a longevity fixture. Because NAD+ itself is hard to dose, most human research uses precursors like nicotinamide riboside. A 2018 randomized, double-blind, placebo-controlled trial in Nature Communications gave it to healthy middle-aged and older adults and found it well tolerated, and it did raise NAD+ levels in the blood [7]. Read the two halves of that sentence separately. Safe over the study period: shown. Raises NAD+: shown. Reverses aging or adds years: not shown, not tested. NAD+ lands in an honest middle, low stakes, early safety data, unproven for the claims that sell it.
Sorted by year, what does the evidence timeline actually reveal?
Line the studies up by publication date and a second pattern appears, separate from strength of evidence. The oldest data here is the 1992 sermorelin study [2], now more than three decades old. The 1997 GHRH dosing study [4] and the 2006 CJC-1295 study [3] sit in the middle. The 2014 ipamorelin trial [5] and 2018 NAD+ trial [7] are newer but still years old. Only the 2023 testosterone trial [1], the 2025 BPC-157 review [6], and the 2026 regulatory update [9] reflect anything close to current thinking.
That spread matters because the peptides with the most social-media momentum, sermorelin and CJC-1295, are also leaning on the oldest human data in the group. Nobody has gone back and re-run those questions with modern trial standards. Not a reason to dismiss the compounds. A reason to notice that “well established” and “recently confirmed” are not the same claim, and the marketing rarely distinguishes between them.
How should the decision actually be sequenced?
Five steps, in this order.
Start with the goal, not the molecule. Genuinely low testosterone with symptoms points to labs and a clinician [1]. Recovery and GH support points to the GH-releasing peptides, with modest, dosing-dependent expectations [2][3][4]. A specific injury someone read about online, usually BPC-157, means choosing the option with the least human evidence [6]. Vague longevity interest points to NAD+, proven safe and proven to raise NAD+, nothing more [7].
Then ask how much is actually known. Testosterone has large trials. The GH-releasing peptides have small, dated ones. BPC-157 has almost none in humans. NAD+ precursors have early safety data only. The less that is known, the more the next step matters.
Then ask who is between the buyer and the vial. For anything unapproved or thinly studied, that is the largest safety variable there is, larger than price, larger than which website loads fastest. For testosterone specifically, the TRAVERSE atrial fibrillation signal means someone needs to be watching after treatment starts [1]. A checkout page cannot do that.
Then check two traps. The 2026 WADA Prohibited List puts peptide hormones, growth factors, and GH secretagogues under class S2 and prohibits them, which sweeps in sermorelin, CJC-1295, and ipamorelin, with testosterone prohibited as well [8]. A “research use only” label offers a tested athlete no protection at all. And regulatory news, like BPC-157’s delisting, is not a safety verdict [9]. Legal, safe, and eligible are three separate questions.
Price comes last. A cheap unverified vial is usually cheap because the clinician, the pharmacy, and the follow-up have been stripped out of the price. That is not a discount. It is a deferred cost.
So what is the shortlist?
Symptoms that sound like low testosterone: start with a blood test and a clinician, not a peptide, because that is where the strong evidence and the required monitoring both live [1].
Recovery and GH support: worth a conversation with a clinician about sermorelin or CJC-1295, expectations set at modest and dosing-dependent [2][3][4].
BPC-157 and NAD+: the two to treat most cautiously. BPC-157 because human evidence barely exists [6] and its legal status is unsettled [9]. NAD+ because the proven benefit is small, even where the safety data looks clean [7].
Every branch of that list ends at the same fork: whoever provides it decides whether it helps or hurts.
Who should actually provide it?
Two groups here, not one, and they are not doing the same job.
| Option | What it actually is | Who decides if it fits |
|---|---|---|
| Supervised telehealth provider | Licensed clinician review, prescription, licensed pharmacy dispensing | A licensed clinician |
| Research-chemical website | “Research use only” powder, seller-issued paperwork | The buyer, alone |
On the supervised side, FormBlends sits first, with HealthRX.com in the same compliant tier, for the same reason that runs through everything above. FormBlends is a physician-supervised telehealth service: a brief assessment, a licensed physician review, a protocol when it fits, and a licensed 503A compounding pharmacy that prepares and ships under sterile standards with cold-chain delivery. Its catalog covers the exact list worked through here, the GH-releasing peptides like sermorelin, recovery compounds like BPC-157, testosterone and its support medications for diagnosed deficiency, and NAD+ on the longevity side. The molecules the research-chemical sites sell as loose powder, a prescriber and a pharmacy handle here instead.
What earns it the top spot is candor as much as structure. FormBlends states plainly that compounded medications are not FDA-approved and that it connects patients to licensed clinicians and pharmacies rather than operating as a medical practice itself. That matches what the studies actually show: testosterone strong only for diagnosed deficiency [1], the GH-releasing peptides real but modest [2][3], BPC-157 close to no human data [6]. A provider that says so out loud is doing the opposite of a site implying everything is proven. Because so much of this category comes down to titration and watching how the body responds, a way to track that matters too. A man logging dose and symptoms over time, for instance with the FormBlends tracker app, brings a real record into a clinician visit instead of a guess. That app is a logging tool, not a checkout page or a prescription pad. The tradeoff is honest: this is a compounded-medication model, most of the catalog is not FDA-approved finished product, and starting means an intake instead of instant checkout. Given everything above, that intake is the safety feature, not friction to route around.
HealthRX.com belongs in the same tier for the same structural reasons: licensed clinical oversight, medically supervised therapy dispensed through proper pharmacy channels rather than sold as a research chemical. Choosing between the two comes down to state licensing and which specific compounds and programs each supports.
Below that line sit the research-chemical retailers: Amino Asylum, Pure Rawz, Core Peptides, and Swiss Chems. Amino Asylum runs a broad, low-priced gray-market catalog. Pure Rawz spans peptides and other research compounds. Core Peptides offers a research-peptide catalog. Swiss Chems sells peptides and related compounds, some carrying their own regulatory baggage. All four label products “for research use only” or “not for human consumption,” and that label is not a technicality, it is the legal basis on which the products are sold at all. The moment one is used the way it is marketed to be used, it becomes an unapproved new drug, which is exactly why the disclaimer exists. None of these four offers a clinician, a prescription, pharmacy dispensing, or follow-up, and none can be reliably ranked against the others on quality, because without independent batch-level testing there is no way to know which one actually ships cleaner product. That single unknown is, in the end, the whole argument for the supervised route.
The honest bottom line
The molecule was never really the question. The order of questions is: what is the goal, how much is actually known about the compound that fits it, who stands between the buyer and the vial, what do the legal and eligibility traps say, and only then, price. Run anything on this list through that sequence and it lands in the same place, a supervised provider, FormBlends first and HealthRX.com in the same tier, with the research-chemical shortcut stripping out precisely the protections the evidence says are needed. Nobody over 40 is really choosing a peptide. They are choosing who is accountable if it does not go as advertised.
What people tend to ask
What is the single most important factor in this decision? Not the compound. Who stands between the buyer and the vial. For anything unapproved or thinly studied, safety depends far more on a licensed clinician’s evaluation, a prescription written when it fits, and a licensed pharmacy’s dispensing than on the molecule or the price tag. A supervised telehealth provider like FormBlends, with HealthRX.com in the same tier, supplies that oversight. A research-chemical website leaves the whole decision to the buyer, alone.
Which compound actually has the strongest evidence? Testosterone, by a wide margin, but only for men with lab-confirmed deficiency and real symptoms. The TRAVERSE trial randomized 5,246 men and found no increase in major cardiac events versus placebo, though it did show more atrial fibrillation [1]. Sermorelin and CJC-1295 have real but small, dated human studies [2][3]. BPC-157 has almost no human data [6]. NAD+ precursors have only early safety data [7].
Is BPC-157 now proven safe and legal, since it was removed from the do-not-compound list? No. Removal from the FDA’s Category 2 list in April 2026 is not approval. A Pharmacy Compounding Advisory Committee meeting is set for July 23 to 24, 2026 to weigh the question [9]. The published literature is still almost entirely preclinical, in animals or cells, with no clinical safety data in humans and no FDA-approved indication [6]. Regulatory movement and proof of safety are two different things.
Is it cheaper, and safer, to just buy from a research-chemical website? Cheaper, usually. Safer, no. Sites like Amino Asylum, Pure Rawz, Core Peptides, and Swiss Chems sell products labeled “for research use only” or “not for human consumption,” and without independent batch-level testing there is no reliable way to know which one ships cleaner product. That single unverifiable gap is why the supervised route wins for every option on the list.
Can a tested athlete use any of these? No. The 2026 WADA Prohibited List places peptide hormones, growth factors, and GH secretagogues under class S2 and prohibits them, which covers sermorelin, CJC-1295, and ipamorelin, and testosterone is prohibited too [8]. A “research use only” label offers a tested athlete zero protection. Legality, safety, and competitive eligibility are three separate checks, not one.
What is the right order to actually make this decision in? Goal first, then how much is actually known about the compound that fits that goal, then who is between the buyer and the vial, then the legal and eligibility traps, then price last. That sequence tends to land most men over 40 at a supervised provider, because that is where the clinician, the pharmacy, and the monitoring the evidence calls for actually exist.
References
- Lincoff AM, et al. “Cardiovascular Safety of Testosterone-Replacement Therapy” (TRAVERSE). N Engl J Med. 2023 (n=5,246; noninferior for MACE; more atrial fibrillation). https://pubmed.ncbi.nlm.nih.gov/37326322/
- Corpas E, et al. “Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.” J Clin Endocrinol Metab. 1992. https://pubmed.ncbi.nlm.nih.gov/1379256/
- Teichman SL, et al. “Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.” J Clin Endocrinol Metab. 2006.
- Vittone J, et al. “Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.” Metabolism. 1997 (less effective than multiple daily doses; modest strength changes).
- Beck DE, et al. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” Int J Colorectal Dis. 2014 (missed primary endpoint, p = 0.15).
- Vasireddi N, et al. “Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.” HSS Journal. 2025 (mostly preclinical; no clinical safety data; no FDA-approved indication).
- Martens CR, et al. “Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults.” Nat Commun. 2018.
- USADA. “2026 WADA Prohibited List” (S2: peptide hormones, growth factors, and GH secretagogues prohibited in sport; testosterone prohibited).
- Frier Levitt. “FDA Peptide Update 2026: Removal from ‘Do Not Compound’ List and What It Means for Pharmacies” (BPC-157 removed from Category 2 in April 2026; PCAC review July 23 to 24, 2026; removal is not approval).
